DMC: Novel celecoxib derivatives to rap cancer: Cancer Biology & Therapy: Vol 4, No 5

167

Views

CrossRef citations to date

Altmetric

Abstract

Commentary to:

Dimethyl-Celecoxib (DMC), a Derivative of Celecoxib that Lacks Cyclooxygenase-2-Inhibitory Function, Potently Mimics the Anti-Tumor Effects of Celecoxib on Burkitt’s Lymphoma In Vitro and In Vivo

Adel Kardosh, Weijun Wang, Jasim Uddin, Nicos A. Petasis, Florence M. Hofman, Thomas C. Chen and Axel H. Schönthal

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

DMC: Novel celecoxib derivatives to rap cancer

Information for

Open access

Opportunities

Help and information

DMC: Novel celecoxib derivatives to rap cancer

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature